PolyOrg — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PolyOrg operates as a specialized chemical CRO/CMO with a strong focus on nucleic acid chemistry and custom organic synthesis. Its primary business involves selling catalog reagents for oligo synthesis and offering fee-for-service contract research and manufacturing. While not a drug developer itself, PolyOrg is a critical enabler for companies in the drug delivery and biologics sectors, particularly those working with oligonucleotides, peptides, and complex small molecules. The company leverages its team of expert Ph.D. chemists to support clients from R&D through to commercial manufacturing.

Drug DeliveryBiologics

Technology Platform

Specialized synthetic organic chemistry platform with core expertise in nucleic acid chemistry (phosphoramidites, PNA monomers) and custom complex molecule synthesis.

Opportunities

Strong growth in oligonucleotide and peptide therapeutic markets drives demand for high-purity building blocks and custom synthesis services.

The biopharma industry's increasing reliance on outsourcing complex chemistry provides a steady stream of potential clients for contract research and manufacturing.

Risk Factors

Faces competition from larger CROs/CMOs and low-cost overseas manufacturers.

Revenue is dependent on a potentially concentrated client base and project-based work, creating volatility.

Supply chain disruptions for specialty raw materials could impact production timelines and costs.

Competitive Landscape

Operates in a competitive CRO/CMO landscape, competing with large players like Thermo Fisher, Sigma-Aldrich (Merck), and dedicated CDMOs, as well as numerous smaller specialty firms. Its differentiation is deep, niche expertise in nucleic acid and PNA chemistry, allowing it to win complex projects that generalists may avoid.

More companies in United States →